A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma

TPS8061Background: Despite the introduction of new compounds to manage relapsed/refractory (R/R) multiple myeloma (MM) over the last decade, none are curative. Trials investigating novel agents or ...